RecruitingNot ApplicableNCT06731998

Optimal Perioperative Pain Control in Minimally Invasive Abdominal Cancer Surgery

Evaluating Optimal Perioperative Pain Management: A Prospective Randomized Control Trial of Laparoscopic Transversus Abdominis Plane Block With Local Anesthetic, Laparoscopic Transversus Abdominis Plane Block Alone, and Local Anesthetic Alone in Minimally Invasive Oncologic Surgery

Sponsor

Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)

Enrollment

48 participants

Start Date

Feb 5, 2025

Study Type

INTERVENTIONAL

Conditions

Gynecologic Cancers Biliary Tract Cancer Cancer Gastrointestinal Cancers Hepatic Cancer Oncologic Surgery Cancer Surgery Gastric (Cardia, Body) Cancer Pancreatic Cancer Resectable

Summary

This is a research study to evaluate the effectiveness of 3 different types of routine pain management regimens used during clinically indicated, minimally invasive oncologic (cancer) surgery. This project is considered "Research" and participation is voluntary. Upon enrollment in this study, the research team will collect data from the patient's medical records. The patient will undergo all of the normal testing and procedures required pre-operatively (standard of care). The study team will then randomly assign the patient (like a flip of a coin) to one of three different study arms for pain management during surgery: 1. Laparoscopic Transversus Abdominis Plane Block (LapTAP) with Local Anesthetic (LA) 2. Laparoscopic Transversus Abdominis Plane Block (LapTAP) only 3. Local Anesthetic (LA) only The patient will receive standard pre- and post-operative care according to clinical guidelines (routine care). The study team will collect information from the patient's medical record for the first 24 hours after their surgery and upon discharge. This information will include pain scores, amount of medication required, any side effects the patient may have experienced, and satisfaction with pain control. Participation in the study will end upon discharge from the hospital.

Eligibility

Min Age: 18 YearsMax Age: 89 Years

Plain Language Summary

Simplified for easier understanding

This study is comparing different pain management approaches used around the time of minimally invasive abdominal cancer surgery (such as laparoscopic or robotic surgery) to identify which methods most effectively reduce pain and opioid use during recovery. **You may be eligible if...** - You are 18–89 years old - You are scheduled for planned (elective) minimally invasive surgery for cancer involving the liver, stomach, gallbladder, pancreas, colon, rectum, ovaries, or other abdominal organs - Your surgery is expected to last between 1 and 8 hours - You are in adequate overall health (ASA physical status I, II, or III) - You are able to rate your own pain on a visual scale **You may NOT be eligible if...** - You have pre-existing liver disease or cirrhosis - You have chronic pain conditions requiring ongoing opioid use - You have serious kidney problems - Your overall health status is very poor (ASA IV or higher) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

PROCEDURELocal Anesthesia

For local anesthetic administration at port sites, 30 mL of 0.1% ropivacaine is injected around the umbilical port site following the completion of the primary surgical procedure. Additionally, 5 mL of 0.1% ropivacaine is injected around each additional port site to ensure effective local anesthesia.

PROCEDURELaparoscopic Transversus Abdominis Plane block

Surgeon will place 18 gauge needle into the fascial plane between the internal oblique and transversus abdominis muscles. Once the needle is accurately positioned surgeon will inject 15 mL of 0.1% ropivacaine slowly. This procedure is performed bilaterally to ensure comprehensive analgesia. The total volume utilized for the LapTAP block is 30 mL of 0.1% ropivacaine.